Trials / Completed
CompletedNCT00635830
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
An Open-Label, Single-Dose, Safety and Tolerability Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 26 Years
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 9 Years – 26 Years
- Healthy volunteers
- Accepted
Summary
To prove that quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine is generally safe and well tolerated in the Chinese population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection. |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2008-03-14
- Last updated
- 2015-10-09
- Results posted
- 2009-08-20
Source: ClinicalTrials.gov record NCT00635830. Inclusion in this directory is not an endorsement.